Drugs / QI-019B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07539233 | Apr 2026 → Aug 2028 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QI-019B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07539233 ↗ |
| Target | CD19 | “QI-019B, the lentiviral vector that carries a BCMA/CD19-targeted CAR” NCT07539233 ↗ |